Prescriber's Corner

Enzalutamide: A New Agent for the Prostate Cancer Treatment Armamentarium

Stephanie B. McCutcheon, PharmD

From Cancer Centers of the Carolinas, a department of the Greenville Hospital System, Greenville, South Carolina

The author has no conflicts of interest to disclose.

Correspondence to: Stephanie B. McCutcheon, PharmD, Cancer Centers of the Carolinas, 65 International Drive, Greenville, SC 29607. E-mail: smccutcheon@ghs.org


J Adv Pract Oncol 2013;4:182–185 | DOI: 10.6004/jadpro.2013.4.3.7 | © 2013 Harborside Press®


  

ABSTRACT

The development of disease resistance to current drugs underlies the need for additional treatment options in metastatic prostate cancer. Learn the key facts about enzalutamide (Xtandi), recently approved for use in patients with castration-resistant disease who have previously taken docetaxel.  




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2016 Harborside Press, LLC All rights reserved.                Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact
Copyright Notice/Disclaimer
Bot trap - Don't go here